letrozole + triptorelin

Letrozole + triptorelin is a combination therapy consisting of letrozole, an aromatase inhibitor, and triptorelin, a gonadotropin-releasing hormone (GnRH) agonist. This regimen is primarily used in premenopausal women with hormone receptor-positive early breast cancer to achieve profound estrogen suppression by combining ovarian function suppression (via triptorelin) with peripheral aromatase inhibition (via letrozole). Letrozole blocks the conversion of androgens to estrogens in peripheral tissues, while triptorelin suppresses pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased ovarian estrogen production. The combination has also been studied for endometriosis-related pain and rare pediatric endocrine disorders[1][2][3][4][5][6].

Brand names

DecapeptylTrelstarFemara

Other names

GnRHa + Letrozoletriprorelin + letrozole